ValuEngine lowered shares of Genomic Health, Inc. (NASDAQ:GHDX) from a hold rating to a sell rating in a research note released on Thursday morning.
Other analysts have also recently issued research reports about the stock. Jefferies Group LLC reissued a hold rating and issued a $34.00 price target on shares of Genomic Health in a research note on Friday, October 20th. Zacks Investment Research raised shares of Genomic Health from a sell rating to a hold rating in a research report on Friday, October 13th. Cowen and Company reaffirmed a hold rating and set a $34.00 price objective on shares of Genomic Health in a research report on Friday, September 1st. Canaccord Genuity reiterated a buy rating and set a $35.00 target price on shares of Genomic Health in a report on Wednesday, September 27th. Finally, BidaskClub lowered shares of Genomic Health from a hold rating to a sell rating in a report on Friday, August 4th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and one has issued a buy rating to the company’s stock. The company presently has an average rating of Hold and a consensus target price of $32.00.
Genomic Health (NASDAQ:GHDX) traded down $0.81 on Thursday, hitting $29.17. 140,100 shares of the company traded hands, compared to its average volume of 118,393. Genomic Health has a 52-week low of $26.37 and a 52-week high of $34.02.
COPYRIGHT VIOLATION NOTICE: “ValuEngine Downgrades Genomic Health, Inc. (GHDX) to Sell” was first published by BBNS and is the property of of BBNS. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at https://baseballnewssource.com/markets/valuengine-downgrades-genomic-health-inc-ghdx-to-sell/1771542.html.
In related news, COO G Bradley Cole sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $31.86, for a total value of $159,300.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider James J. Vaughn sold 1,379 shares of Genomic Health stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $32.51, for a total transaction of $44,831.29. The disclosure for this sale can be found here. In the last ninety days, insiders sold 21,379 shares of company stock worth $676,131. Insiders own 46.20% of the company’s stock.
Several large investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its position in shares of Genomic Health by 6.8% in the second quarter. Vanguard Group Inc. now owns 1,670,622 shares of the medical research company’s stock valued at $54,379,000 after buying an additional 106,452 shares during the last quarter. Renaissance Technologies LLC lifted its position in shares of Genomic Health by 10.9% during the second quarter. Renaissance Technologies LLC now owns 813,300 shares of the medical research company’s stock worth $26,473,000 after purchasing an additional 80,100 shares in the last quarter. State Street Corp lifted its position in shares of Genomic Health by 2.5% during the second quarter. State Street Corp now owns 517,313 shares of the medical research company’s stock worth $16,840,000 after purchasing an additional 12,696 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its position in shares of Genomic Health by 1.2% during the third quarter. Schwab Charles Investment Management Inc. now owns 503,244 shares of the medical research company’s stock worth $16,150,000 after purchasing an additional 5,904 shares in the last quarter. Finally, Eagle Asset Management Inc. raised its holdings in Genomic Health by 18.4% in the second quarter. Eagle Asset Management Inc. now owns 379,473 shares of the medical research company’s stock valued at $12,351,000 after acquiring an additional 58,920 shares in the last quarter. 89.13% of the stock is owned by institutional investors and hedge funds.
About Genomic Health
Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with our FREE daily email newsletter.